Bluejay Diagnostics, Inc. cash flow to debt ratio of -5.04K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bluejay Diagnostics, Inc.'s free cash flow has increased -23.37% from $-8.13M last year to $-6.23M, signaling increasing performance

Bluejay Diagnostics, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Bluejay Diagnostics, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.02 today, signaling strengthened financials

Bluejay Diagnostics, Inc. has a net cash position, so leverage is healthy.

Bluejay Diagnostics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Bluejay Diagnostics, Inc. has insufficient data to evaluate this check.

Bluejay Diagnostics, Inc.'s short-term assets of $5.46M exceed its short-term liabilities of $1.12M

Bluejay Diagnostics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bluejay Diagnostics, Inc.'s return on equity of -144.27%, is lower than 15.00%, indicating bad performance

Bluejay Diagnostics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Bluejay Diagnostics, Inc. has insufficient public price history to evaluate earnings stability.

Bluejay Diagnostics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Bluejay Diagnostics, Inc. has negative free cash flow, indicating cash burn

Bluejay Diagnostics, Inc.'s yearly earnings has increased -11.26% since last year from $-7.72M to $-6.85M, signaling increasing performance

Bluejay Diagnostics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -163.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bluejay Diagnostics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Bluejay Diagnostics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Bluejay Diagnostics, Inc. has insufficient public price history to evaluate ROE consistency.

Bluejay Diagnostics, Inc. has insufficient data to evaluate this check.

Bluejay Diagnostics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bluejay Diagnostics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Bluejay Diagnostics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Bluejay Diagnostics, Inc. has insufficient data to evaluate this check.

Bluejay Diagnostics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Bluejay Diagnostics, Inc. has a price-to-book ratio of 0.11x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Bluejay Diagnostics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue